Lysogene Announces first European patient treated in AAVance, Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)
Go back to Lysogene Announces first European patient treated in AAVance, Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)| Heelys, Inc. (NASDAQ: LYS) | Delayed: 0.74 -0.07 (8.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.81 | 52 Week High | $0.74 | |||
| Open | $0.79 | 52 Week Low | $0.70 | |||
| Day High | $0.74 | P/E | 1.64 | |||
| Day Low | $0.70 | EPS | $0.45 | |||
| Volume | 3,421 | |||||
